A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group
暂无分享,去创建一个
R. Goldsby | K. Janeway | R. Gorlick | M. Krailo | R. Womer | C. Morris | M. Isakoff | E. Kolb | D. Villaluna | P. Hingorani | J. Doski | A. Collier | Michael S. Isakoff
[1] J. Reid,et al. A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) , 2018, Pediatric blood & cancer.
[2] Robin L. Jones,et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Prados,et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.
[4] D. Hawkins,et al. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Blay,et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.
[6] R. Goldsby,et al. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.
[7] P. Meltzer,et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Meltzer,et al. Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma , 2014, Clinical Cancer Research.
[9] S. Keir,et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[10] P. Adamson,et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study , 2013, Pediatric blood & cancer.
[11] S. Klaar,et al. The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use , 2012, Clinical Cancer Research.
[12] M. Trivedi,et al. Eribulin: A Novel Cytotoxic Chemotherapy Agent , 2012, The Annals of pharmacotherapy.
[13] J. Blay,et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. , 2011, The Lancet. Oncology.
[14] Sarika Jain,et al. Eribulin Mesylate , 2011, Clinical Cancer Research.
[15] Peter J Houghton,et al. Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.
[16] P. Adamson,et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study , 2010, Pediatric blood & cancer.
[17] S. Altekruse,et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Adamson,et al. Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group , 2010, Clinical Cancer Research.
[19] M. Jordan,et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase , 2008, Molecular Cancer Therapeutics.
[20] Joseph Zeidner,et al. The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.
[21] M. Semik,et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Ferrari,et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] A. Cantor,et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. , 1995, Medical and pediatric oncology.
[24] A. Huvos,et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Meyer,et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis , 1992, Cancer.
[26] N. Jaffe,et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. , 1974, The New England journal of medicine.
[27] D. James,et al. VINCRISTINE IN CHILDREN WITH MALIGNANT SOLID TUMORS. , 1964, The Journal of pediatrics.
[28] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[29] M. Krailo,et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. , 1987, Medical and pediatric oncology.